<DOC>
	<DOC>NCT01182441</DOC>
	<brief_summary>This is a prospective, randomized, multicenter study to provide additional information on the safety and efficacy of the WATCHMAN LAA Closure Technology. The PREVAIL study was amended to initiate a prospective, non-randomized continued access study titled "Continued Access to PREVAIL (CAP2)" to collect additional information on the safety and efficacy of the WATCHMAN LAA closure technology. The study is estimated to enroll an initial cohort of 300 subjects with a maximum of 1500 subjects, at 60 investigational sites in the U.S.</brief_summary>
	<brief_title>Evaluation of the WATCHMAN LAA Closure Device in Patients With Atrial Fibrillation Versus Long Term Warfarin Therapy</brief_title>
	<detailed_description />
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Warfarin</mesh_term>
	<criteria>Key Paroxysmal, persistent or permanent nonvalvular AF Eligible for longterm warfarin therapy Eligible to come off warfarin therapy Calculated CHADS2 score of 2 or greater. Also patients with a CHADS2 score of 1 may be included if any of the following apply: Female age 75 or older Baseline LVEF â‰¥ 30 and &lt; 35% Aged 6574 and has diabetes or coronary artery disease Aged 65 or greater and has congestive heart failure Key Contraindicated/allergic to aspirin Indicated for clopidogrel therapy or has taken clopidogrel within 7 days prior to enrollment History of atrial septal repair or has an ASD/PFO device Implanted mechanical valve prosthesis NYHA Class IV CHF Resting heart rate &gt; 110 bpm Participated previously in the PROTECT AF or CAP Registry studies Key Echo LVEF &lt; 30% Existing pericardial effusion &gt; 2mm High risk PFO Significant mitral valve stenosis Complex atheroma with mobile plaque of the descending aorta and/or aortic arch Cardiac tumor</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>atrial fibrillation</keyword>
	<keyword>stroke</keyword>
	<keyword>TIA</keyword>
	<keyword>trans ischemic attack</keyword>
	<keyword>warfarin</keyword>
	<keyword>Coumadin</keyword>
</DOC>